The currently funded Emory-CDC Clinical Trials Unit (Emory-CDC CTU) is ideally positioned to implement the mission of NIAID and to conduct clinical trials developed by the NIH HIV/AIDS Clinical Trials Networks. The Emory-CDC CTU is supported by Emory?s rich scientific milieu with numerous synergistic grants and various thematic research centers covering all network priority areas, as well as the support and experience of our CDC partners. The Emory-CDC CTU is comprised of 5 CRSs with well-established programs and histories of performing NIH funded clinical research. In this renewal the Emory-CDC CTU will be expanding to a 6th CRS in Mexico City.
Our specific aims are the following: 1. To contribute scientific expertise and human subject enrollment into studies that address these four key research areas: Adult HIV therapeutic strategies, including HIV cure, noninfectious comorbidities, and the infectious comorbidities of hepatitis and tuberculosis; strategies to address HIV and HIV-associated infections in pediatric and maternal populations; integrated HIV prevention strategies; and vaccines to prevent HIV infection. 2. To be a leading CTU for contributions of women, minorities, and adolescents to support network clinical trials, both domestically and in low and middle-income countries. 3. To operate an efficient and flexible CTU that can respond rapidly to evolving research opportunities. 4. To participate in the development and implementation of the clinical research plans of all the NIAID clinical research networks that are addressing the four priority areas.
The Emory-CDC Clinical Trials Unit is well positioned to contribute to the mission of the NIH HIV/AIDS Clinical Trials Networks due to our extensive experience in conducting clinical trials related to Hepatitis/TB/HIV vaccine, prevention, and treatment both domestically and internationally. We are well suited to participate in pediatric maternal and adult populations. Through our partnerships with the CDC, and our diverse scientific collaborators, we are poised to help develop and implement the next generation of network research plans.
|Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912|
|Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187|
|Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459|
|Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524|
|Latkin, Carl A; Van Tieu, Hong; Fields, Sheldon et al. (2017) Social Network Factors as Correlates and Predictors of High Depressive Symptoms Among Black Men Who Have Sex with Men in HPTN 061. AIDS Behav 21:1163-1170|
|Anderson, Albert M; Lennox, Jeffrey L; Mulligan, Mark M et al. (2017) Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals. J Neurovirol 23:106-112|
|Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111|
|Rolle, Charlotte-Paige; Rosenberg, Eli S; Siegler, Aaron J et al. (2017) Challenges in Translating PrEP Interest Into Uptake in an Observational Study of Young Black MSM. J Acquir Immune Defic Syndr 76:250-258|
|Riddler, Sharon A; Aga, Evgenia; Bosch, Ronald J et al. (2016) Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. J Infect Dis 213:556-60|
|Anderson, Albert M; Lennox, Jeffrey L; Nguyen, Minh L et al. (2016) Preliminary study of a novel cognitive assessment device for the evaluation of HIV-associated neurocognitive impairment. J Neurovirol 22:816-822|
Showing the most recent 10 out of 81 publications